IGF1 and Parkinson disease: Treatment with recombinant IGF1 by intraperitoneal injection significantly reduced the loss of dopaminergic neurons in the SNpc and improved functional deficits in animals injected with a PD-inducing neurotoxin in the striatum [35, 36].